Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4.
AuthorsShaw, David M
Ryan, Matthew G
Myers, Kevin A
Kingsman, Susan M
Carroll, M W
Stern, Peter L
AffiliationCRC Immunology Group, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractThe oncofoetal antigen 5T4 is a 72 kDa glycoprotein expressed at the cell surface. It is defined by a monoclonal antibody, mAb5T4, that recognises a conformational extracellular epitope in the molecule. Overexpression of 5T4 antigen by tumours of several types has been linked with disease progression and poor clinical outcome. Its restricted expression in non-malignant tissue makes 5T4 antigen a suitable target for the development of antibody directed therapies. The use of murine monoclonal antibodies for targeted therapy allows the tumour specific delivery of therapeutic agents. However, their use has several drawbacks, including a strong human anti-mouse immune (HAMA) response and limited tumour penetration due to the size of the molecules. The use of antibody fragments leads to improved targeting, pharmacokinetics and a reduced HAMA. A single chain antibody (scFv) comprising the variable regions of the mAb5T4 heavy and light chains has been expressed in Escherichia coli. The addition of a eukaryotic leader sequence allowed production in mammalian cells. The two 5T4 single chain antibodies, scFv5T4WT19 and LscFv5T4, described the same pattern of 5T4 antigen expression as mAb5T4 in normal human placenta and by FACS. Construction of a 5T4 extracellular domain-IgGFc fusion protein and its expression in COS-7 cells allowed the relative affinities of the antibodies to be compared by ELISA and measured in real time using a biosensor based assay. MAb5T4 has a high affinity, K(D)=1.8x10(-11) M, as did both single chain antibodies, scFv5T4WT19 K(D)=2.3x10(-9) M and LscFv5T4 K(D)=7.9x10(-10) M. The small size of this 5T4 specific scFv should allow construction of fusion proteins with a range of biological response modifiers to be prepared whilst retaining the improved pharmacokinetic properties of scFvs.
CitationIsolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4. 2000, 1524 (2-3):238-46 Biochim. Biophys. Acta
JournalBiochimica et Biophysica Acta
- Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.
- Authors: Woods AM, Wang WW, Shaw DM, Ward CM, Carroll MW, Rees BR, Stern PL
- Issue date: 2002 Aug 15
- Pharmacokinetics and biodistribution of genetically-engineered antibodies.
- Authors: Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK
- Issue date: 1998 Dec
- High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.
- Authors: Roovers RC, Henderikx P, Helfrich W, van der Linden E, Reurs A, de Bruïne AP, Arends JW, de Leij L, Hoogenboom HR
- Issue date: 1998 Dec
- Construction of mono- and bivalent human single-chain Fv fragments against the D antigen in the Rh blood group: multimerization effect on cell agglutination and application to blood typing.
- Authors: Furuta M, Uchikawa M, Ueda Y, Yabe T, Taima T, Tsumoto K, Kojima S, Juji T, Kumagai I
- Issue date: 1998 Mar
- Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
- Authors: Beiboer SH, Reurs A, Roovers RC, Arends JW, Whitelegg NR, Rees AR, Hoogenboom HR
- Issue date: 2000 Feb 25